Allarity Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $320.0K | $0 |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $6.6M | $6.1M |
| SG&A Expense | $6.3M | $11.4M |
| Operating Income | $-12.6M | $-27.2M |
| Operating Margin | -3,939.1% | — |
| Interest Expense | — | — |
| Pretax Income | $-11.2M | $-24.9M |
| Income Tax Expense | $0 | $-381.0K |
| Net Income | $-11.2M | $-24.5M |
| Net Margin | -3,509.7% | — |
| EPS (Basic) | $-0.78 | $-1.74 |
| EPS (Diluted) | — | — |
| Shares Outstanding (Basic) | 14.4M | 14.5M |
| Shares Outstanding (Diluted) | 14.4M | 14.5M |
| Dividends Per Share | — | — |